Marc S. Ernstoff
Roswell Park Comprehensive Cancer Center(US)National Institutes of Health(US)National Cancer Institute(US)Center for Cancer Research(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immune Cell Function and Interaction
Most-Cited Works
- → Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline(2018)3,616 cited
- → Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited
- → Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.(1996)2,101 cited
- → Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group(2017)1,943 cited
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial(2012)1,080 cited